Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2016

View Archived Issues

Bayer initiates phase I trial of BAY-1436032 in patients with IDH1-R132X mutant solid tumors

Janssen initiates first-in-human study of JNJ-61186372 in advanced NSCLC

Hikma acquires a portfolio of six injectable products in Europe

Xencor and Novartis establish bispecific collaboration

FDA places clinical hold on Regulus' IND for RG-101 for chronic HCV infection

University of Michigan conducts first-in-human studies for new PET tracers

Puma submits MAA to the EMA for neratinib

The Jackson Laboratory patents DNA repair inhibitors

EMA recommends approval of Keytruda for advanced NSCLC

Shanghai Sun-Sail Pharmaceutical Science & Technology describes antituberculosis compounds

GW Pharmaceuticals announces positive phase III pivotal trial results for Epidiolex

LabCorp announces launch of Roche cobas EGFR Mutation Test v2

Agilis Biotherapeutics receives CRADA

RhoU GTPase shows promise as a therapeutic target for MM

Bristol-Myers Squibb receives new breakthrough therapy designation for Opdivo

First-in-human results for ONO-4232

FDA grants priority review to Ocrevus BLA for relapsing and primary progressive forms of MS

Carbavance meets primary endpoints in phase III TANGO 1 study in patients with cUTI

IL-22 linked to aberrant bone formation in spondyloarthropathies

European Commission approves Zavicefta for serious bacterial infections

PolypDx urine-based diagnostic test for adenomatous polyps launched in U.S.

Spero Therapeutics presents new MvfR inhibitor for P. aeruginosa infections

FDA accepts Advanced Accelerator Applications' NDA for Lutathera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...